Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Stoke Therapeutics, Inc. (STOK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "Stoke Therapeutics, Inc. Consolidated balance sheets June 30, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 192,060 $ 113,556 Marketable securities 39,387 116,039 Prepaid expenses 10,950 10,932 Other current assets 3,699 2,955 Interest receivable 136 588 Total current assets $ 246,232 $ 244,070 Restricted cash 569 569 Operating lease right-of-use assets 3,646 4,753 Property and equipment, net 6,472 6,675 Total assets $ 256,919 $ 256,067 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,556 $ 766 Accrued and other current liabilities 12,222 15,748 Deferred revenue - current portion 8,059 14,880 Total current liabilities $ 21,837 $ 31,394 Deferred revenue - net of current portion 43,258 36,856 Other long term liabilities 1,629 2,968 T..."
07/25/2023 8-K Quarterly results
05/04/2023 8-K Quarterly results
03/15/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome"
03/06/2023 8-K Quarterly results
Docs: "Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates – Company expects to complete Phase 1/2a studies of STK-001 in children and adolescents with Dravet syndrome in 2023 in order to initiate a Phase 3 program in 2024 –"
02/03/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amended and Restated Bylaws of Stoke Therapeutics, Inc. (as amended and restated on February 2, 2023)"
01/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation, dated as of January 2023"
12/02/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
Docs: "Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – 2H 2022 clinical data readout on track for patients with Dravet syndrome who received multiple doses of STK-001 in Phase 1/2a clinical studies MONARCH, ADMIRAL, and SWALLOWTAIL –"
03/10/2022 8-K Quarterly results
02/17/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/10/2022 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Other Ev...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Presentation, dated as of January 2022",
"SAN DIEGO, CA and BEDFORD, MA, January 10, 2022 -"
12/17/2021 8-K Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics  Interactive Data
12/03/2021 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – Company nominates STK-002 as clinical candidate for the treatment of autosomal dominant optic atrophy , the most common inherited optic nerve disorder –"
09/21/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation, dated as of September 2021"
09/09/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
06/09/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
02/05/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/20/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement",
"Opinion of Fenwick & West LLP",
"Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering BEDFORD, Mass., November 19, 2020 - Stoke Therapeutics, Inc. , a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $39.00 per share. The gross proceeds from this offering are expected to be $97.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Stoke. The offering is expected to close on or about November 24, 2020, subject to the satisfaction of customary closing conditions. Stoke has also granted the underwriters a 30-day option to purchase up to an ..."
11/12/2020 8-K Quarterly results
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company ...",
"Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates"
10/07/2020 8-K Quarterly results
08/21/2020 8-K Quarterly results
08/17/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
07/09/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company ...",
"Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company's Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy